Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, has received two drug license suspension orders from the Drugs Control Administration in Telangana. The first order, from the Assistant Director in Nalgonda, suspends a store's drug license for five days (effective 30 May 2026), with a potential revenue loss of Rs 0.85 lakhs. The second order, from the Assistant Director in Serilingampalli, suspends another store's drug license for two days with a potential revenue loss of Rs 0.18 lakhs. The violations are cited under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. The combined quantified revenue impact is approximately Rs 1.03 lakhs.
The suspension orders are short-term and the quantifiable financial impact is small (around Rs 1.03 lakhs). However, the regulatory action highlights a compliance risk related to the subsidiary's pharmacy operations in Telangana, which could draw attention from investors concerned about operational governance.